«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

22卷

期数:

2016年05期

页码:

421-423

栏目:

临床医学

出版日期:

2016-09-20

文章信息/Info

Title:

Analysis of therapeutic effect on patients with BCLC -B hepatocellular carcinoma

文章编号:

1006-8147（2016）05-0421-3

作者:

郑 鹏; 李 强

(天津医科大学肿瘤医院肝胆肿瘤科,国家肿瘤临床医学研究中心,天津市“肿瘤防治”重点实验室,天津300060)

Author(s):

ZHENG Peng;  LI Qiang

（Department of Hepatobiliary Carcinoma ， Cancer Institute and Hospital ， Tianjin Medical University，National Clinical Research Center of Cancer ，Tianjin Key Laboratory of Cancer Prevention and Therapy， Tianjin 300060 ，China）

关键词:

肝细胞肝癌; 巴塞罗那肝癌分期; 肝切除术; 介入治疗

Keywords:

hepatocellular carcinoma' target="_blank" rel="external">">hepatocellular carcinoma; Barcelona Clinic Liver Cancer staging system; liver resection; transarterial embolization

' target="_blank" rel="external">" />

分类号:

R735.7

DOI:

-

文献标志码:

A

摘要:

目的：分析手术切除对比介入治疗对巴塞罗那（BCLC）分期中B期肝细胞肝癌患者的效果。方法：回顾性分析99例BCLC-B期肝细胞肝癌患者的临床资料，并将手术切除组进一步细分为2个亚组，分析各组间无病生存期及总生存期间差异。结果：手术组与介入组之间1年、2年、3年总生存率分别为81.3%、53.9%、33.1%和59.7%、42.5%、16.8%，差异具有统计学意义（P＝0.024）；手术组亚组B1组与B2组的1年、2年、3年的无病生存率分别为67.5%、58.9%、43.0%和63.6%、34.6%、17.1%，差异具有统计学意义（P＝0.047）。结论：选择恰当的BCLC中B期的患者能够从手术切除中获益。

?

Abstract:

Objective：To analyze the impact of liver resection (LR) on patients with hepatocellular carcinoma (HCC) at the Barcelona ClinicLiver Cancer (BCLC)-B stage. Methods：Ninety-nine patients with BCLC-B HCC were included in this study. Survival and recurrence analyses were performed by log-rank tests andχ² tests. Further analyses were specifically carried out for the HCC subclassification (B1 and B2) proposed recently. Results: Ninety-nine patients were included, and three-year survival rates were 81.3%，53.9%，33.1% and 59.7%，42.5%，16.8%，respectively (P = 0.024) for surgery group and TAE group. In the surgical subgroup analysis, one, two and three-year disease free rates were 67.5%, 58.9%, 43.0% and 63.6%, 34.6%, 17.1%, respectively(P =0.047). No significant difference was observed in the overall survival analysis. Conclusion: BCLC-B stage HCC may be still a complex group, according to the updated criteria of B-stage subclassifications and selected BCLC-B stage patients may benefit from liver resection.

参考文献/References:

[1]Ciria R, López-Cillero P, Gallardo A B, et al. Optimizing the management of patients with BCLC stage-B hepatocellular carcinoma: Modern surgical resection as a feasible alternative to transarterial chemoemolization[J]. Eur J Surg Oncol, 2015, 41(9): 1153
[2]Bolondi L, Burroughs A, Dufour J , et al. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions[J]. Semin Liver Dis, 2012, 32(4): 348
[3]中国抗癌协会肝癌专业委员会．原发性肝癌的临床诊断与分期标准[J]．现代实用医学，2002，14（4）：213
[4]Marrero J A, Fontana R J, Barrat A, et al. Prognosis of hepatocellular carcinoma:comparison of 7 staging systems in an American cohort[J]. Hepatology, 2005, 41(4): 707[5]Poon R T, Fan S T, Lo C M, et al. Extended hepatic resection for hepatocellular carcinoma in patients with cirrhosis: Is it justified?[J]. Ann Surg, 2002, 236(5): 602
[6]Ishizawa T, Hasegawa K, Aoki T, et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma[J]. Gastroenterology, 2008, 134(7): 1908
[7]Makuuchi M, Sano K. The surgical approach to HCC: our progress and results in Japan[J]. Liver Transpl, 2004, 10(2 Suppl 1): S46
[8]Arii S, Tanaka S, Mitsunori Y, et al. Surgical strategies for hepatocellular carcinoma with special reference to anatomical hepatic resection and intraoperative contrast-enhanced ultrasonography[J]. Oncology, 2010, 78(Suppl 1): 125
[9]European Association for the Study of Liver Disease. European organisation for the treatment of cancer. EASL-EORTC clinical practice guidelines:management of hepatocellular carcinoma[J]. J Hepatol, 2012, 56(4): 908

相似文献/References:

[1]袁华尊,孙保存,赵秀兰,等.Amotl2促进肝细胞肝癌血管生成拟态及EMT形成[J].天津医科大学学报,2016,22(04):277.
　YUAN Hua-zun,SUN Bao-cun,ZHAO Xiu-lan,et al.Amotl2 promotes vasculogenic mimicry and epithelial-mesenchymal transition in hepatocellular carcinoma[J].Journal of Tianjin Medical University,2016,22(05):277.
[2]张宁,赵秀兰,李勇莉,等.Nrf2促进肝癌细胞的迁移与侵袭能力[J].天津医科大学学报,2020,26(05):408.
　ZHANG Ning,ZHAO Xiu-lan,LI Yong-li,et al.Nrf2 promotes the migration and invasion in hepatocellular carcinoma[J].Journal of Tianjin Medical University,2020,26(05):408.
[3]温鹏,韩玉娟,杨剑,等.肝细胞癌患者缩短普美显强化MRI检查中肝胆期时间的探索[J].天津医科大学学报,2022,28(04):433.
　WEN Peng,HAN Yu-juan,YANG Jian,et al.Exploration of shortening the duration of hepatobiliary phase in EOB enhanced MRI for patients with hepatocellular carcinoma[J].Journal of Tianjin Medical University,2022,28(05):433.
[4]李茗鹤,白楠,孙笑,等.GCLM调控肝细胞肝癌细胞增殖及机制研究[J].天津医科大学学报,2024,30(04):305.[doi:10.20135/j.issn.1006-8147.2024.04.0305]
　LI Minghe,BAI Nan,SUN Xiao,et al.Study on the regulation and mechanism of GCLM in cell proliferation of hepatocellular carcinoma cells[J].Journal of Tianjin Medical University,2024,30(05):305.[doi:10.20135/j.issn.1006-8147.2024.04.0305]

备注/Memo

备注/Memo:

作者简介 郑鹏（1989-），男，硕士在读，研究方向：肝胆胰肿瘤的临床与基础研究；通信作者：李强，E-mail:liqiang4016@yahoo.com。

常用功能

更新日期/Last Update: 2016-09-20